Originally published on NZ Herald
Pharmac board chairman Steve Maharey is backing an early access scheme that would give patients access to new and emerging drugs faster.
Maharey told the Herald that while Pharmac’s core business was sound, it was a model under stress.
Pharmaceuticals and medical devices were changing with increasing speed and the migration of new ideas around the world was much faster, Maharey said.
“The biggest mega-trend that’s affecting Pharmac is that trend to need to respond more quickly to innovations in new medicines, and will be in medical devices, and to put them into practice once they’ve been evaluated,” he said.
“That process can clearly be, and has been identified by everybody as being, slow and the pressure on that system will get greater and greater.”
Pharmac, the Government’s drug-buying agency with a budget of $985 million, is responsible for the procurement of medicines for district health boards and will soon also take on the management of all medical devices as well.
That includes all consumable from tongue depressors to pacemakers.
A fast-moving issue
Maharey said the logical outcome of the rapidly moving pharmaceutical and device market was speeding up the process, but not all of it because most of Pharmac was working well.
“It would be very difficult simply to speed up the whole lot, spending a billion dollars faster all the time. The other thing is that most things are working just fine.”
Maharey is talking about what he refers to as the edge of the issue, the part of Pharmac that is most often criticised – funding of new and emerging medicines and technology.
“The edge of this issue is fast-moving, so that means early access, the logical thing which is what we are looking at as an agency.”
Labour, while in Opposition, repeatedly called for an early access scheme for patients seeking faster access to new medicines but the proposal has not gone any further.
Prime Minister Jacinda Ardern recently revived the idea when she asked Health Minister David Clark for some advice.
Maharey, whose wife Liz Mackay died of cancer in 2004, said Pharmac was working with the Ministry of Health to look at all the early access processes around the world to try to identify what might be the best way forward.
“Personally, I would very much like to see something like this happen. As I said, we’ve identified that leading edge area as something that we simply must have some policy that will help us address that.”
He cautioned that it was not a policy that should be rushed into.
“I think a pilot would be a better way to go so we don’t lurch into something which may cost a lot of money and not get a lot of progress.
“I would like to think something will happen but that will be a decision made a little higher than my pay grade.”
UK improves early access
The UK has had the Early Access to Medicines Scheme since 2015 which aims to give people access to promising new drugs that are not yet licensed.
Earlier this month, British Health Minister Nicola Blackwood outlined changes that promised even faster access to new medicines through its Accelerated Access Collaborative (AAC).
The AAC would be the single point of contact for innovators keen to get their products into the NHS. The establishment of a “global leading” testing infrastructure was also planned.
Maharey, a former Labour cabinet minister, denied he’d been brought in by the Government as a fixer but said Pharmac was undergoing a “refresh”.
“Are there some things that are causing it some stress? Yes there are.
“It’s got a very prescribed role which is to provide the best health outcomes it possibly can for the wider population of New Zealand. That’s its core role and I think everyone agrees it does that core role very well.”
The board had recently been working on how Pharmac’s core activities could be improved, increasing transparency and addressing the early access issues those for rare diseases.
“Governments all over the world are struggling with this because the prices are astronomical and pharmaceutical companies clearly see this as a major new area of revenue for them so they are pushing those medicines a lot,” Maharey said.
New Zealand behind on new drugs
Medicines New Zealand general manager Graeme Jarvis agreed Pharmac needed to be refreshed in terms of both timeliness and transparency of decision-making.
“As far as getting access to modern medicines for patients and making timely funding decisions, New Zealand has for some years now ranked in last place out of 20 comparable OECD countries including Spain, Italy, the UK and Australia. New Zealand is consistently a long way behind these other countries,” Jarvis said.
On the board of Medicines NZ are representatives of pharmaceutical companies including Sanofi, GSK, Merck, Sharpe and Dohme, Roche, Pfizer and Novartis.
Jarvis said Pharmac’s decision-making processes were far too slow as evidenced by a waiting list of more than 100 medicines which had been recommended for funding by Pharmac’s expert technical committee but not funded.